If this is not your name, click here.
| | If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| |  PN27,1 Safety Study Follow-Up Produces Continuing Favorable Results ITHACA, N.Y., Oct. 17, 1996 -- Paracelsian, Inc. (Nasdaq: PRLN) announced today the results of its five-month follow-up of cancer patients treated in their first safety study of PN27,1 (AndroCar(TM)). Results of the initial three-month safety study indicated that AndroCar(TM) was generally well tolerated up to the highest dose administered. Adverse reactions, occurring in three of the nine patients, were mild and self-limiting. During this post-study period, each of the patients tolerated AndroCar(TM) with no further adverse reactions reported. Patient progress is as follows: the breast cancer patient has experienced continued decreases in her serum CEA biomarker concentrations to near normal levels; a 59-year-old male patient with non-Hodgkin's lymphoma was declared in remission by his physician while taking only AndroCar(TM) during the post-study period; a prostate cancer patient, with a hormone-insensitive form of the disease, experienced a halting of his serum PSA increases from the second month of the initial three-month study through two months of the follow-up period; the remaining two patients entered the initial three-month study in remission and remained in remission during the post-study follow-up. All patients reported experiencing increased energy and improved concentration with AndroCar(TM). "We continue to be satisfied with the safety profile of AndroCar(TM) and are encouraged by the progress experienced by these patients," said John Babish, Vice President and Chief Science Officer. "We believe we are observing meaningful data that we hope to repeat in a larger number of patients in the next two trials," he said. Paracelsian recently changed its clinical trial program by replacing its extension of the initial safety trial with two additional compassionate-use safety trials. One is a prostate specific trial with approximately 35 patients and the other trial, with approximately 12 patients, is unrestricted as to cancer type. Both trials are designed to ensure patient safety at three doses administered over a 90-day period. Results are expected to be available in June 1997. This clinical trial program will enable the Company to collect patient data on a larger number of diverse cancer patients but also collect a uniform set of data from prostate cancer patients specifically. Paracelsian is a biotechnology company engaged in the discovery of pharmaceuticals from herbal sources. Its discoveries are accomplished by applying the Company's proprietary screening technology, based in signal transduction, to its library of extracts used in Traditional Chinese Medicine. Paracelsian recently announced its plans to launch its first non-prescription products, AndroVir(TM) for AIDS patients, in March 1997, and AndroCar(TM), in July 1997.
|
